ITGAL: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of ITGAL. The page also collects GeneMedi's different modalities and formats products for ITGAL in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the ITGAL target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
ITGAL encodes the integrin alpha L chain. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This I-domain containing alpha integrin combines with the beta 2 chain (ITGB2) to form the integrin lymphocyte function-associated antigen-1 (LFA-1), which is expressed on all leukocytes. LFA-1 plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Target ID | GM-T35640 |
Target Name | ITGAL |
Gene ID | 3683 |
Gene Official Name | ITGAL |
Gene Alias | CD11A, LFA-1, LFA1A |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index |
Pre-made ITGAL-specific INN-index biosimilar (antibody&conjugates)-odulimomab, rovelizumab, Efalizumab
Anti-ITGAL therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Order |
GMP-Bios-INN-931 | Pre-Made Odulimomab Biosimilar, Fab Fusion, Anti-Itgal Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody | odulimomab | ITGAL | Fab Fusion | ![]() | |
GMP-Bios-INN-981 | Pre-Made Rovelizumab Biosimilar, Bispecific, Anti-Itgal;Itgb2 Antibody: Anti-CD11A/LFA-1/LFA1A;CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 therapeutic antibody | rovelizumab | ITGAL;ITGB2 | Bispecific | ![]() | |
GMP-Bios-ab-166 | Pre-Made Efalizumab biosimilar, Whole mAb, Anti-ITGAL Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody | Efalizumab | ITGAL | Whole mAb | ![]() |
Pre-made anti-ITGAL inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-ITGAL benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-ITGAL mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cat No. | Antibody Name | Format | Classified by tag | Order |
GM-Tg-hg-T35640-Ab | Anti-ITGAL monoclonal antibody | mab | Biofunctional antibody, Therapeutics Target antibody | ![]() |